• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Background Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is
recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable …

Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …

Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by
cardiac hypertrophy (wall thickness≥ 15 mm) that is not explained by abnormal loading …

Importance Previous data on septal myectomy (SM) and alcohol septal ablation (ASA) in
obstructive hypertrophic cardiomyopathy have been limited to small, nonrandomized, single …

Mitral valve abnormalities were not part of modern pathological and clinical descriptions of
hypertrophic cardiomyopathy in the 1950s, which focused on left ventricular (LV) …

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often
inherited primary cardiac disease, has now transformed into a contemporary highly treatable …

Treatment of progressive heart failure, due to left ventricular (LV) outflow tract obstruction
and elevated intraventricular systolic pressures, has been a major component of …